Trials / Sponsors / Ambrx, Inc.
Ambrx, Inc.
Industry · 4 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors | Phase 2 | 2021-11-05 |
| Active Not Recruiting | ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) HER2 Positive Metastatic Breast Cancer | Phase 2 | 2021-10-26 |
| Completed | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Breast Neoplasms, Gastric Neoplasm, Solid Tumors | Phase 1 | 2018-03-20 |
| Completed | Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (G Growth Hormone Deficiency | Phase 2 | 2008-07-01 |